FLC3 Antibody

What is FLT3 and why is it an important target for antibody development?

FLT3 (FMS-like tyrosine kinase 3), also known as Flk-2 (fetal liver kinase) and Stk-1 (stem cell tyrosine kinase), is a class III receptor tyrosine kinase similar to KIT and FMS receptors. FLT3 is primarily expressed on hematopoietic stem/progenitor cells and is a critical target for antibody development due to its significant role in the development and progression of acute myeloid leukemia (AML). The protein contains an extracellular region with five immunoglobulin-like domains and an intracellular region with a split kinase domain, making it a structurally complex but important target for research and therapeutic development . FLT3's limited expression in tissues outside the hematopoietic system further enhances its value as a specific target for both research and potential therapeutic applications .

What are the key differences between mouse and human FLT3 antibodies?

Mouse and human FLT3 antibodies target species-specific variants of the FLT3 receptor, with mouse Flt-3 sharing approximately 85% amino acid sequence identity with human Flt-3 . This high level of conservation indicates significant structural similarity, but the 15% difference is sufficient to necessitate species-specific antibodies for optimal experimental outcomes. Human FLT3 antibodies typically target epitopes within the human FLT3 sequence (such as Asn27-Asn541), while mouse antibodies target corresponding regions in the mouse sequence (like Gly27-Arg188) . When selecting an antibody for cross-species applications, researchers must verify cross-reactivity experimentally, as even small differences in epitope structure can significantly impact binding affinity and experimental results.

What experimental applications are validated for FLT3 antibodies?

FLT3 antibodies have been validated for multiple experimental applications, including:

• ELISA (Enzyme-Linked Immunosorbent Assay): FLT3 antibodies can function as detection antibodies when paired with appropriate capture antibodies, allowing for quantitative assessment of FLT3 protein levels .

• Flow Cytometry: Antibodies such as the Goat Anti-Human Flt-3/Flk-2 have been validated for detecting FLT3 expression on cell surfaces, such as in THP-1 human acute monocytic leukemia cell lines .

• Western Blotting: FLT3 antibodies can detect the protein in recombinant samples and cell lysates, enabling analysis of protein expression and modification states .

• Immunocytochemistry: These antibodies have been used to visualize FLT3 localization in fixed cells, as demonstrated with HT-2 mouse T cell lines where specific staining was localized to the cytoplasm .

• Neutralization Assays: Some FLT3 antibodies have neutralizing capabilities, allowing researchers to block FLT3 signaling in functional studies .

How should FLT3 antibodies be stored and handled to maintain optimal activity?

For optimal maintenance of FLT3 antibody activity, researchers should follow these evidence-based storage and handling protocols:

• Storage Temperature: Store antibodies at -20°C to -70°C for long-term stability (up to 12 months from date of receipt) .

• Short-term Storage: For ongoing experiments, antibodies can be stored at 2-8°C under sterile conditions for up to 1 month after reconstitution .

• Freeze-Thaw Cycles: Use a manual defrost freezer and avoid repeated freeze-thaw cycles, which can compromise antibody structure and function .

• Reconstitution: When reconstituting lyophilized antibodies, use sterile techniques and appropriate buffers as specified in the product documentation.

• Long-term Storage After Reconstitution: Reconstituted antibodies can be stored at -20°C to -70°C for up to 6 months under sterile conditions .

How can FLT3 antibodies be effectively used to study AML progression and treatment response?

FLT3 antibodies offer sophisticated approaches for studying AML progression and treatment response through multiple methodological applications:

• Flow Cytometric Monitoring: Researchers can employ FLT3 antibodies to monitor changes in FLT3 expression levels on AML blasts before, during, and after treatment. This technique allows for quantitative assessment of receptor density and distribution on cell populations, providing insights into disease progression dynamics .

• Bispecific Antibody Applications: Advanced FLT3-CD3 bispecific antibodies, such as the 7370 IgG-based bispecific antibody, can be used to study T cell-mediated cytotoxicity against AML cells. These experiments reveal important mechanistic insights into immunotherapeutic approaches, particularly at varying effector-to-target (E:T) ratios. Studies have shown that even at low E:T ratios (1:20), significant cytotoxicity can be observed against FLT3-expressing AML cells .

• Combination Therapy Models: FLT3 antibodies can be used in conjunction with small molecule FLT3 inhibitors to study potential synergistic effects and resistance mechanisms. This approach helps researchers understand how dual targeting strategies might overcome limitations of single-agent therapies .

• Patient-Derived Xenograft Models: By using FLT3 antibodies in flow cytometry panels to track engraftment and expansion of patient-derived AML cells in immunocompromised mice, researchers can evaluate therapeutic strategies in models that more closely recapitulate human disease heterogeneity.

What factors affect the specificity and sensitivity of FLT3 antibody-based detection methods?

Several critical factors influence the specificity and sensitivity of FLT3 antibody-based detection methods:

• Epitope Selection and Accessibility: Antibodies targeting different epitopes of FLT3 demonstrate varying sensitivities based on epitope accessibility. Extracellular domain epitopes (e.g., Asn27-Asn541 in human FLT3) are more accessible in intact cells, while intracellular domains require cell permeabilization techniques .

• FLT3 Expression Levels: Detection sensitivity correlates with target abundance. Studies with cell lines representing high (EOL-1), medium (MOLM-13), and low (MV4-11) FLT3 expression levels demonstrate that detection sensitivity and experimental outcomes vary accordingly .

• FLT3 Mutational Status: Wild-type and mutant FLT3 (particularly internal tandem duplication [ITD] mutations) may exhibit different epitope conformations, potentially affecting antibody binding efficiency. Researchers should validate antibodies against both wild-type and relevant mutant forms for comprehensive studies .

• Technical Variables:

  • Fixation protocols significantly impact epitope preservation

  • Buffer composition affects background signal and specific binding

  • Secondary antibody selection influences signal amplification

  • Instrument settings in flow cytometry require optimization for FLT3 detection ranges

• Cross-Reactivity Considerations: The 85% sequence homology between mouse and human FLT3 necessitates careful antibody selection to avoid cross-reactivity issues, particularly in models using both human and mouse cells .

How do FLT3-targeted bispecific antibodies compare with small molecule inhibitors in research applications?

FLT3-targeted bispecific antibodies and small molecule inhibitors represent distinct research tools with complementary advantages and limitations:

The bispecific antibody approach offers significant advantages for studying broader AML populations irrespective of FLT3 mutational status, with the 7370 anti-FLT3-CD3 IgG-based bispecific antibody demonstrating complete elimination of both FLT3 wild-type (EOL-1) and FLT3 mutant cell lines (MOLM-13) in preclinical models . This contrasts with small molecule inhibitors that typically show variable efficacy depending on specific mutations.

What methodological challenges exist when using FLT3 antibodies to study hematopoietic stem/progenitor cells?

Researchers face several methodological challenges when applying FLT3 antibodies to hematopoietic stem/progenitor cell studies:

• Distinguishing FLT3 Expression Levels: FLT3 expression is restricted to highly enriched stem/progenitor cell populations, requiring sensitive detection methods to distinguish between subtly different expression levels that may indicate distinct cellular states or differentiation stages . Flow cytometric protocols must be optimized for rare cell detection with appropriate compensation and gating strategies.

• Potential Antibody-Mediated Signaling: FLT3 antibody binding may inadvertently trigger receptor signaling, potentially altering the biological state of the cells under investigation. Researchers must determine whether their experimental antibodies have agonistic, antagonistic, or neutral effects on FLT3 signaling.

• Co-expression Analysis Complexity: Comprehensive stem cell identification requires simultaneous analysis of FLT3 with other stem cell markers. This necessitates complex multi-color flow cytometry panels with careful consideration of fluorophore selection to avoid spectral overlap with FLT3 antibody conjugates.

• Off-Target Effects on Non-Target Cell Populations: When studying mixed cell populations, researchers must account for potential effects on non-target cells. For instance, studies have shown that FLT3 ligand-producing tumors do not expand mature innate lymphoid cells (ILCs) in the periphery, demonstrating the specificity of FLT3 effects on particular hematopoietic lineages .

• Potential Toxicity to Normal Hematopoietic Stem Cells: A major consideration when using FLT3-targeted approaches is potential toxicity to normal hematopoietic stem cells. Studies with therapeutic FLT3-CD3 bispecific antibodies have observed dose-dependent reductions in hematopoietic stem/progenitor cells (HSPCs) in vitro, necessitating careful dosing strategies and toxicity monitoring in research applications .

How can researchers optimize neutralization assays with FLT3 antibodies?

Optimizing neutralization assays with FLT3 antibodies requires systematic methodological refinement:

• Determining Optimal Antibody Concentration: Establish the Neutralization Dose (ND₅₀) through dose-response experiments. For example, studies with mouse FLT3 antibodies have shown that the ND₅₀ typically ranges from 0.05-0.25 μg/mL when neutralizing 10 ng/mL of Recombinant Mouse Flt-3 Ligand .

• Cell Line Selection: Choose appropriate responder cell lines that demonstrate consistent FLT3-dependent responses. The BaF3 mouse pro-B cell line transfected with mouse Flt-3 has been successfully used to demonstrate dose-dependent proliferation in response to FLT3 ligand and subsequent neutralization by FLT3 antibodies .

• Assay Readout Optimization: Select appropriate readout methods based on the biological response being measured:

  • Proliferation assays for growth-related responses

  • Phospho-flow cytometry for signaling pathway activation

  • Gene expression analysis for transcriptional responses

• Temporal Considerations: Establish appropriate time points for measuring neutralization effects, as both early signaling events and later biological responses may be relevant depending on experimental objectives.

• Positive and Negative Controls: Include critical controls:

  • FLT3 ligand alone (positive control for stimulation)

  • Irrelevant antibody of matching isotype (control for non-specific effects)

  • Known neutralizing antibody (comparative standard)

By systematically addressing these parameters, researchers can develop robust neutralization assays that accurately assess the functional inhibitory capacity of FLT3 antibodies against ligand-induced responses.

What are the most common causes of false positives/negatives in FLT3 antibody-based assays?

False results in FLT3 antibody-based assays can arise from multiple sources that researchers should systematically address:

False Positives:

False Negatives:

• Epitope Masking: Certain fixation or permeabilization protocols may mask the FLT3 epitope. For example, some antibodies require milder fixation conditions to preserve epitope recognition. Test multiple fixation protocols when optimizing immunostaining procedures.

• Insufficient Antibody Concentration: Using suboptimal antibody concentrations may result in weak or undetectable signals. Titration experiments are essential to determine optimal concentrations for each application.

• Low Target Expression: In cells with low FLT3 expression (like MV4-11), sensitive detection methods may be required. Signal amplification strategies or more sensitive detection systems should be considered .

• Technical Limitations: Improper antibody storage (repeated freeze-thaw cycles) can degrade antibody function. Follow manufacturer recommendations for storage at -20°C to -70°C and avoid repeated freeze-thaw cycles .

How can contradictory FLT3 expression data between different detection methods be reconciled?

Contradictory FLT3 expression data between detection methods requires systematic analysis and reconciliation:

• Method-Specific Sensitivities: Different detection platforms have inherent sensitivity thresholds. Flow cytometry typically detects surface expression while Western blotting measures total protein. Discrepancies may reflect these methodological differences rather than true biological variance.

• Epitope Accessibility Variations: Antibodies targeting different epitopes may yield contradictory results due to:

  • Differential glycosylation affecting epitope exposure (FLT3 has 10 potential N-linked glycosylation sites)

  • Conformational changes induced by mutations or ligand binding

  • Protein-protein interactions masking specific epitopes

• Reconciliation Strategies:

  • Employ multiple antibodies targeting different epitopes within FLT3

  • Utilize complementary detection methods (e.g., flow cytometry, Western blotting, and immunofluorescence)

  • Incorporate molecular techniques like RT-PCR to quantify transcript levels

  • Consider protein turnover and trafficking dynamics that may affect different detection methods

• Control Sample Validation: When faced with contradictory results, validate techniques using well-characterized control samples with known FLT3 expression profiles, such as EOL-1 (high expression), MOLM-13 (medium expression), and MV4-11 (low expression) cell lines .

• Quantitative Considerations: Convert qualitative observations to quantitative measurements whenever possible. For example, flow cytometry results should be reported as median fluorescence intensity (MFI) rather than simply "positive" or "negative" to facilitate more precise comparisons between methods.

What control experiments are essential when using FLT3 antibodies in complex biological systems?

When employing FLT3 antibodies in complex biological systems, these essential control experiments ensure experimental validity:

• Isotype Controls: Include matched isotype controls to distinguish specific from non-specific binding, particularly in flow cytometry applications. For example, when using Goat Anti-Human Flt-3/Flk-2 antibody, appropriate isotype controls (e.g., AB-108-C) should be incorporated .

• Biological Positive and Negative Controls:

  • Positive Controls: Include cell lines with well-characterized FLT3 expression (e.g., THP-1, EOL-1) .

  • Negative Controls: Incorporate cell lines known to lack FLT3 expression.

• Expression Knockdown/Knockout Validation: For definitive specificity confirmation, compare antibody binding between wild-type cells and those with FLT3 knockdown/knockout. This control is particularly valuable in novel or poorly characterized systems.

• Cross-Blocking Experiments: Use competitive binding assays with unlabeled antibodies to confirm epitope-specific binding versus non-specific interactions.

• Recombinant Protein Controls: Include purified recombinant FLT3 protein as a standard in quantitative assays. Recombinant Human Flt-3/Flk-2 Fc Chimera has been successfully used in Western blot applications to validate antibody specificity .

• Multiple Antibody Validation: When possible, confirm results using alternative antibodies targeting different FLT3 epitopes to strengthen confidence in expression patterns.

• Functional Controls for Neutralizing Antibodies: When using neutralizing FLT3 antibodies, include dose-response curves to demonstrate specific inhibition of FLT3-mediated functions, as demonstrated in cell proliferation assays with BaF3 cells expressing mouse Flt-3 .

How are FLT3 antibodies being integrated into multiparametric analysis platforms?

FLT3 antibodies are being strategically integrated into sophisticated multiparametric analysis platforms through several innovative approaches:

• Mass Cytometry (CyTOF) Integration: FLT3 antibodies have been adapted for CyTOF-ready applications, allowing simultaneous analysis of FLT3 expression alongside dozens of other parameters without fluorescence spectrum limitations . This technology enables comprehensive characterization of rare hematopoietic stem/progenitor populations in both normal and malignant contexts.

• Spectral Flow Cytometry Panels: Advanced spectral flow cytometry platforms now incorporate FLT3 antibodies in high-dimensional panels that simultaneously assess multiple stemness markers, differentiation antigens, and functional parameters. This enables nuanced classification of cellular hierarchies and identification of phenotypically distinct leukemic subpopulations.

• Spatial Transcriptomics and Protein Analysis: Emerging platforms combine FLT3 antibody detection with spatial transcriptomics to correlate protein expression with gene expression patterns in intact tissue contexts. This provides insights into the microenvironmental regulation of FLT3 expression and signaling.

• Single-Cell Multi-Omics Approaches: Integration of FLT3 antibody-based detection with single-cell RNA sequencing and epigenetic profiling creates multi-dimensional datasets that connect surface FLT3 expression with underlying transcriptional and epigenetic states at single-cell resolution.

• Computational Analysis Integration: Machine learning algorithms now incorporate FLT3 expression data from antibody-based detection as a critical parameter in predictive models for leukemia classification, risk stratification, and treatment response prediction.

What are the current limitations of FLT3 antibodies in therapeutic applications?

Despite their promise, FLT3 antibodies face several significant limitations in therapeutic contexts that researchers must address:

• On-Target, Off-Tumor Toxicity: FLT3 expression on normal hematopoietic stem/progenitor cells creates an inherent risk of hematological toxicity. Studies with FLT3-CD3 bispecific antibodies have observed dose-dependent reductions in HSPCs in vitro, indicating potential for unintended effects on normal hematopoiesis that requires careful monitoring and management .

• Limited Penetration in Bone Marrow Niches: The bone marrow microenvironment, where leukemic stem cells reside, presents physical and biological barriers to antibody penetration. This may limit effectiveness against deeply sequestered leukemic populations that drive relapse.

• Modulation of Surface FLT3 Expression: Exposure to antibodies or therapy-induced stress can alter surface expression of FLT3 through internalization or transcriptional downregulation, potentially limiting sustained targeting efficiency.

• Heterogeneous Expression in AML: Variable FLT3 expression across and within patient samples complicates therapeutic targeting. Studies using cell lines with high (EOL-1), medium (MOLM-13), and low (MV4-11) FLT3 expression demonstrate differential sensitivity to FLT3-targeted approaches .

• Immunogenicity Concerns: First-generation bispecific FLT3 antibodies derived from mouse sequences posed immunogenicity risks. While newer fully human formats (like the 7370 bispecific antibody) mitigate this concern, they still require extensive safety monitoring .

• Compensatory Signaling Pathways: AML cells may activate alternative signaling pathways to circumvent FLT3 blockade, necessitating combination approaches that address multiple survival mechanisms simultaneously.

How do recent advances in antibody engineering impact FLT3-targeted research?

Recent advances in antibody engineering are transforming FLT3-targeted research through multiple technological innovations:

• IgG-Based Bispecific Formats: The development of full-length IgG-based FLT3-CD3 bispecific antibodies (like 7370) represents a significant advancement over earlier formats. These engineered antibodies maintain the favorable pharmacokinetic properties of conventional IgG molecules while incorporating dual targeting functionality . The IgG backbone confers extended half-life and improved manufacturability compared to earlier bispecific formats.

• Site-Specific Conjugation Technologies: Advanced conjugation methods enable precise attachment of payloads or reporters to FLT3 antibodies without compromising binding affinity or increasing heterogeneity. This allows researchers to develop highly consistent antibody-drug conjugates or imaging probes with reproducible pharmacological properties.

• Affinity Modulation Engineering: Structure-guided engineering now enables fine-tuning of FLT3 antibody affinity to optimize the balance between tumor targeting and normal tissue binding. In the case of therapeutic applications, this helps manage potential toxicity to normal hematopoietic stem cells while maintaining efficacy against leukemic blasts.

• Fc Engineering for Enhanced Functionality: Modifications to the Fc domain of FLT3 antibodies can dramatically alter their functional properties:

  • Silent Fc variants minimize unwanted effector functions

  • Enhanced ADCC variants amplify natural killer cell recruitment

  • Extended half-life mutations improve pharmacokinetic profiles

  • pH-sensitive binding enables targeted intracellular delivery

• Multispecific Antibody Platforms: Beyond bispecific formats, trispecific and multispecific antibodies incorporating FLT3 binding domains alongside other targeting moieties are emerging as powerful research tools for studying complex cellular interactions and signaling network relationships.

What methodological considerations are important when validating novel FLT3 antibodies for research use?

Validating novel FLT3 antibodies requires a comprehensive methodological approach addressing multiple parameters:

• Epitope Characterization:

  • Determine the specific binding region (e.g., Asn27-Asn541 for human FLT3)

  • Assess whether the epitope is conserved across species (considering the 85% sequence identity between mouse and human FLT3)

  • Evaluate epitope accessibility in different cellular contexts (surface vs. intracellular)

• Specificity Validation:

  • Test against recombinant FLT3 proteins from multiple species

  • Validate using cell lines with varying FLT3 expression levels (e.g., EOL-1, MOLM-13, MV4-11)

  • Confirm specificity using knockout/knockdown approaches

  • Assess cross-reactivity with related receptor tyrosine kinases (KIT, FMS)

• Functional Characterization:

  • Determine whether the antibody has neutralizing activity against FLT3 signaling

  • Establish the Neutralization Dose (ND₅₀) if applicable

  • Assess potential agonistic activity that might inadvertently activate FLT3 signaling

• Application-Specific Validation:

  • For flow cytometry: optimize staining conditions, fluorophore conjugation, and confirm with isotype controls

  • For ELISA: validate as capture or detection antibody in sandwich formats

  • For Western blotting: confirm detection of appropriate molecular weight species under reducing and non-reducing conditions

  • For immunohistochemistry/immunocytochemistry: optimize fixation and antigen retrieval protocols

• Reproducibility Assessment:

  • Evaluate lot-to-lot consistency

  • Test stability under various storage conditions (-20°C to -70°C long-term; 2-8°C short-term)

  • Assess performance after reconstitution and multiple freeze-thaw cycles

What are the key considerations for selecting the optimal FLT3 antibody for specific research applications?

Selecting the optimal FLT3 antibody requires systematic evaluation of multiple parameters aligned with research objectives:

• Species Compatibility: Choose antibodies specifically validated for your experimental species. Consider that mouse and human FLT3 share 85% sequence identity, but species-specific antibodies typically offer superior performance for their intended targets .

• Application Suitability: Select antibodies explicitly validated for your intended application:

  • For flow cytometry: Anti-Human Flt-3/Flk-2 antibodies have been validated on THP-1 cells

  • For ELISA: Validated antibody pairs like Mouse Anti-Human Flt-3/Flk-2 Monoclonal capture with Goat Anti-Human Flt-3/Flk-2 detection

  • For functional studies: Neutralizing antibodies with established ND₅₀ values (0.05-0.25 μg/mL for mouse FLT3)

• Epitope Considerations: Select antibodies targeting epitopes appropriate for your research question:

  • Extracellular domain antibodies (e.g., targeting Asn27-Asn541) for surface detection

  • Antibodies recognizing both wild-type and mutant FLT3 for comprehensive AML studies

  • Antibodies with known neutralizing capacity for functional inhibition studies

• Validation Documentation: Prioritize antibodies with comprehensive validation data:

  • Demonstrated specificity via knockout/knockdown controls

  • Performance data across multiple cell lines with varying expression levels

  • Lot-to-lot consistency information

• Format and Modifications: Consider specialized formats for specific applications:

  • Bispecific formats (like 7370) for T cell recruitment studies

  • Fluorophore-conjugated antibodies for direct flow cytometry

  • Biotinylated formats for detection system flexibility

How should researchers approach data integration from FLT3 antibody-based assays with other experimental platforms?

Effective integration of FLT3 antibody-based data with other experimental platforms requires systematic methodological approaches:

• Standardized Sample Processing: Establish unified sample preparation protocols that maintain compatibility across multiple analytical platforms. This minimizes technical variation when comparing results from antibody-based detection with other methods.

• Quantitative Normalization Strategies:

  • Utilize standardized controls across all platforms (e.g., reference cell lines with known FLT3 expression levels)

  • Implement computational normalization methods that account for platform-specific detection biases

  • Develop conversion factors to facilitate direct comparison between antibody-based signals and transcript expression values

• Temporal Coordination: When integrating data across platforms, carefully align sampling timepoints to account for differences between transcript-level changes (often occurring earlier) and protein-level alterations detected by antibodies.

• Multimodal Single-Cell Approaches: Leverage technologies that permit simultaneous analysis of surface FLT3 protein (via antibody detection) and gene expression or epigenetic state in the same cells. This approach eliminates the need to reconcile data from separate experiments.

• Pathway-Level Integration: Focus integration efforts on biological pathway activities rather than isolated measurements. For example, correlate FLT3 surface expression (antibody-based) with downstream signaling activities (phospho-flow or transcriptional targets) to construct more complete biological models.

• Data Visualization Frameworks: Develop visualization tools that simultaneously display antibody-derived FLT3 measurements alongside complementary data types to facilitate pattern recognition and hypothesis generation.

What quality control measures should be implemented when working with FLT3 antibodies in longitudinal studies?

Longitudinal studies using FLT3 antibodies require robust quality control measures to ensure data integrity across experimental timepoints:

• Reference Standard Implementation: Maintain consistent reference standards throughout the study duration:

  • Cryopreserved aliquots of reference cell lines (e.g., THP-1, EOL-1)

  • Recombinant FLT3 protein standards from single manufacturing lots

  • Stabilized control samples with known FLT3 expression profiles

• Antibody Lot Management:

  • Purchase sufficient antibody quantities from single manufacturing lots when possible

  • Perform lot-to-lot comparison studies when transitions are unavoidable

  • Document and track lot numbers used for each experimental timepoint

• Instrument Calibration Protocols:

  • For flow cytometry: implement regular calibration with standardized beads

  • For ELISA: include standard curves on each plate and monitor curve parameters

  • For imaging: maintain consistent acquisition settings and validate with fluorescence standards

• Environmental Standardization:

  • Maintain consistent laboratory conditions throughout the study

  • Document any deviations in temperature, humidity, or other relevant parameters

  • Process samples using standardized protocols at consistent times of day

• Monitoring Antibody Performance:

  • Regularly test antibody binding to reference standards

  • Track signal-to-noise ratios over time

  • Document antibody storage conditions and freeze-thaw cycles

• Statistical Process Control:

  • Implement Levey-Jennings charts to monitor assay performance

  • Establish acceptance criteria for control measurements

  • Define procedures for assay failure and sample retesting